Nasal Decongestion and Obstructive Sleep Apnea

Does Nasal Decongestion Improve Obstructive Sleep Apnea ?

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00630474

Enrollment

Registered

2008-03-07

Start date

2004-01-31

Completion date

2005-04-30

Last updated

2009-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Sleep Apnea Syndrome, Rhinitis

Keywords

sleep apnea, rhinitis

Brief summary

Whether impaired nasal breathing contributes to sleep related breathing disturbances has not been known. Therefore, the purpose of the study is to compare the effect of xylometazoline, a drug that decongests the nasal mucosa when applied locally, with placebo in terms of sleep and nocturnal breathing and daytime performance.

Interventions

DRUGxylometazoline

xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

20 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Obstructive sleep apnea syndrome (excessive sleepiness, apnea/hypopnea index \>10/h) * Chronic nasal congestion (complaint of impaired nasal breathing that interfered with subjective sleep quality on at least 3 nights per week during at least the last 3 months)

Exclusion criteria

* Nasal surgery within the last 6 months * Current treatment with nasal decongestants or topical steroids * Sleep disorders other than obstructive sleep apnea * Internal medical or psychiatric disorders that interfered with sleep

Design outcomes

Primary

Measure	Time frame
sleep related breathing disturbances sleep efficiency daytime sleepiness	at end of one week treatment

Countries

Switzerland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026